Editing B2M and CIITA to Create Hypoimmune Cell Lines for Cell Therapy
29 August 2023
Gene editing is a viable approach for reducing immunogenicity of iPSC-derived therapeutic cells. The B2M and CIITA HLA-regulatory genes are good targets.
Which stem cell reprogramming technology should I use?
17 October 2019
Wondering which stem cell reprogramming technology you should use for your iPSC project? Discover the pros and cons of RNA Reprogramming from REPROCELL.
Tissue Sourcing for the Development of iPSC-derived Disease Models
06 February 2019
Looking to source primary tissues for iPSC generation? Find out more about tissue sourcing for the development of iPSC-derived disease models.